Major Depressive Disorder

Intra-Cellular Therapies has submitted an sNDA for lumateperone for the treatment of major depressive disorder in adults as adjunctive therapy to antidepressants.

Recent research finds that after ECT, pro-inflammatory cytokines decreased significantly, and anti-inflammatory cytokines increased in teenagers with depression.

Let’s compare treatment risks when managing mixed states.

According to new data, NeuroStar Advanced TMS helped nearly 60% of adolescents with major depressive disorder.

The FDA has granted clearance to the Horizon Inspire transcranial magnetic stimulation system to treat major depressive disorder, obsessive-compulsive disorder, and anxious depression.

How can you distinguish bipolar mixed states? Stay tuned in this short series.

Patients who have experienced a perinatal loss are at increased risk of MDD, anxiety disorders, and trauma-related disorders.

Learn more about a specific subset of mood disorders.

A refined rTMS protocol, the Stanford Accelerated Intelligent Neuromodulation Therapy for major depressive disorder, shows promise in bipolar disorder.

It’s time to address adult ADHD.

Although safety and tolerability was positive, ALTO-100 failed to reach primary endpoint in MDD study.

Adjunctive rTMS for antidepressant nonresponders? Researchers performed a randomized comparison with current antidepressant treatment approaches.

Recent research has highlighted important functional aspects of vitamin D. Learn more here.

Baseline clinical factors and early improvement in overall and specific depressive symptoms predict response to rTMS in patients with depression.

The FDA has granted Fast Track designation to liafensine for the treatment of patients with treatment-resistant depression.

As a treatment, low-dose lithium can act like a bridge between medications and integrative approaches, supporting well-being with reduced adverse effects.

Reports of suicidality with GLP-1RA antiobesity medication are supported by analysis of WHO data, but no association is found in large population cohort study or analysis of clinical trials.

John Krystal, MD, explores the future of ketamine and psychedelics in psychiatry, shedding light on their potential to improve patient care by increasing options treatment options.

The FDA instead issued a CRL for MDMA-assisted psychotherapy for PTSD, requesting an additional phase 3 trial to examine safety and efficacy. Other psychedelic compounds are proceeding with trials for psychiatric conditions. Learn more here.

Will this help my sleep and mood? Researchers investigated the effects of noninvasive neurostimulation on sleep quality and depressive symptoms in patients with major depressive disorder in a meta-analysis of randomized controlled trials.

Abbott has initiated the TRANSCEND study to evaluate the use of deep brain stimulation to manage treatment-resistant depression.

Phase 2 trials suggest extended-release oral ketamine formulations could be alternative to clinic-administered treatment for resistant depression.

What is new in research on major depressive disorder?

Diagnostic clarity between anhedonia and persistent depressive disorder is paramount in clinical practice to ensure effective and safe treatment for patients.

For older adults, hoarding disorder can have serious consequences. Examine this case study to learn more.

Esmethadone missed primary efficacy measure in phase 3 clinical trial after robust results in phase 2, possibly more to differences in the cohorts than the compound.

Will this procedure help? Researchers investigated early symptom improvement and other clinical predictors of response to repetitive transcranial magnetic stimulation for depression.

SSRI and SNRI antidepressants were deemed the safest classes of antidepressants in the event of excess dosing in an assessment of 14 antidepressants prescribed in the United States on 3 safety indices.

A supplemental New Drug Application has been submitted to the FDA seeking approval of esketamine (Spravato) CIII nasal spray as a monotherapy for adults with treatment-resistant depression.

This randomized, placebo-controlled, phase 3 clinical trial showed that a 14-day treatment course of oral zuranolone 50 mg/day in MDD led to significantly greater improvements in depressive symptoms when compared with placebo.